Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDR001 in KRAS/NRAS Mutated or Non-Actionable NSCLC
NCT03693326Phase 2Unknown
- Sponsor
- Asan Medical Center
- Start
- Nov 2018
- Primary completion
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of spartalizumab in non-small cell lung cancer (NSCLC), sponsored by Asan Medical Center. Primary endpoint: Objective Response Rate up to 13.8 months. Status: unknown.
02
Drugs
spartalizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03693326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03693326.